Our top pick for
BioCardia, Inc is a biotechnology business based in the US. BioCardia shares (BCDA) are listed on the NASDAQ and all prices are listed in US Dollars. BioCardia employs 24 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$1.91 - $6.50|
|50-day moving average||$4.07|
|200-day moving average||$3.54|
|Wall St. target price||$12.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.20|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$-9,668,000|
|Return on assets TTM||-62.41%|
|Return on equity TTM||-139.27%|
|Market capitalisation||$59.4 million|
TTM: trailing 12 months
There are currently 421,847 BioCardia shares held short by investors – that's known as BioCardia's "short interest". This figure is 8% down from 458,311 last month.
There are a few different ways that this level of interest in shorting BioCardia shares can be evaluated.
BioCardia's "short interest ratio" (SIR) is the quantity of BioCardia shares currently shorted divided by the average quantity of BioCardia shares traded daily (recently around 166737.94466403). BioCardia's SIR currently stands at 2.53. In other words for every 100,000 BioCardia shares traded daily on the market, roughly 2530 shares are currently held short.
However BioCardia's short interest can also be evaluated against the total number of BioCardia shares, or, against the total number of tradable BioCardia shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioCardia's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 BioCardia shares in existence, roughly 30 shares are currently held short) or 0.0334% of the tradable shares (for every 100,000 tradable BioCardia shares, roughly 33 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioCardia.
Find out more about how you can short BioCardia stock.
We're not expecting BioCardia to pay a dividend over the next 12 months.
BioCardia's shares were split on a 1:9 basis on 5 June 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioCardia shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for BioCardia shares which in turn could have impacted BioCardia's share price.
Over the last 12 months, BioCardia's shares have ranged in value from as little as $1.91 up to $6.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCardia's is 2.0696. This would suggest that BioCardia's shares are significantly more volatile than the average for this exchange and represent a higher risk.
BioCardia, Inc. , a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California. .
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.